-- Adam Koppel, 10% Owner, Director, on April 16, 2026, executed a purchase for 1,562,500 shares in Kailera Therapeutics (KLRA) for $25,000,000. Following the Form 4 filing with the SEC, Koppel has control over a total of 22,583,268 common shares of the company, with 22,583,268 controlled indirectly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/2096997/000119312526164407/xslF345X05/ownership.xml